{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:49:02Z","timestamp":1789044542046,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005809","name":"hyderabad eye research foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Topiramate (TPM) is a drug commonly used by neurophysicians and psychiatrists for a plethora of indications. Topiramate has been reported to induce acute angle closure glaucoma as an adverse effect. However, there is limited literature on Topiramate causing hypopyon uveitis and intense ocular inflammation. It is imperative for ophthalmologists as well as physicians to be aware of the potential sight threatening ocular adverse effects of Topiramate. We report 2 rare consecutive cases of severe hypopyon uveitis and choroidal detachments after using Topiramate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>Two patients presented with sudden onset of angle closure, bilateral hypopyon uveitis and choroidal detachments. On reassessing a detailed treatment history, it was found that both patient were taking oral Topiramate which had been started 2\u2009weeks before the onset of ocular symptoms. The bilateral hypopyon and angle closure were considered to be induced by Topiramate and the drug was discontinued. The patients were started on oral and topical steroids which led to resolution of hypopyon uveitis and choroidal detachments. The visual acuity improved and the intraocular pressure also got normalised in both the cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Topiramate can lead to a bilateral hypopyon uveitis and severe ocular inflammation. An urgent cessation of topiramate along with topical and systemic steroids is required to prevent serious complications.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12886-021-02050-x","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T07:03:11Z","timestamp":1627369391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Topiramate induced bilateral hypopyon uveitis and choroidal detachment: a report of two cases and review of literature"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9211-917X","authenticated-orcid":false,"given":"Mudit","family":"Tyagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashwat","family":"Behera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirisha","family":"Senthil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev R.","family":"Pappuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Ambiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Dikshit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"issue":"2","key":"2050_CR1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1684\/j.1950-6945.2004.tb00053.x","volume":"6","author":"E Spina","year":"2004","unstructured":"Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord. 2004;6(2):57\u201375.","journal-title":"Epileptic Disord"},{"issue":"1","key":"2050_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0002-9394(01)01013-3","volume":"132","author":"JT Banta","year":"2001","unstructured":"Banta JT, Hoffman K, Budenz DL, Ceballos E, Greenfield DS. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol. 2001;132(1):112\u20134. https:\/\/doi.org\/10.1016\/S0002-9394(01)01013-3.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"2050_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/09273948.2010.523805","volume":"19","author":"MH Jabbarpoor Bonyadi","year":"2011","unstructured":"Jabbarpoor Bonyadi MH, Soheilian R, Soheilian M. Topiramate-induced bilateral anterior uveitis associated with hypopyon formation. Ocul Immunol Inflamm. 2011;19(1):86\u20138. https:\/\/doi.org\/10.3109\/09273948.2010.523805.","journal-title":"Ocul Immunol Inflamm"},{"key":"2050_CR4","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2147\/OPTH.S104847","volume":"10","author":"JL Goldberg","year":"2016","unstructured":"Goldberg JL, Lau AG, Fan B, Ford L, Greenberg HE. Is uveitis associated with topiramate use? A cumulative review. Clin Ophthalmol. 2016;10:1467\u201370. https:\/\/doi.org\/10.2147\/OPTH.S104847.","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"2050_CR5","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.4103\/ijo.IJO_1192_17","volume":"66","author":"P Mahendradas","year":"2018","unstructured":"Mahendradas P, Parab S, Sasikumar R, Kawali A, Shetty BK. Topiramate-induced acute angle closure with severe panuveitis: a challenging case report. Indian J Ophthalmol. 2018;66(9):1342\u20134. https:\/\/doi.org\/10.4103\/ijo.IJO_1192_17.","journal-title":"Indian J Ophthalmol"},{"key":"2050_CR6","doi-asserted-by":"publisher","first-page":"bcr2014203787","DOI":"10.1136\/bcr-2014-203787","volume":"2014","author":"YY Pikkel","year":"2014","unstructured":"Pikkel YY. Acute bilateral glaucoma and panuveitis as a side effect of topiramate for weight loss treatment. BMJ Case Rep. 2014;2014:bcr2014203787.","journal-title":"BMJ Case Rep"},{"issue":"2","key":"2050_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10792-013-9793-8","volume":"34","author":"S Kamal","year":"2014","unstructured":"Kamal S, Yadava U, Kumar S, Goel R. Topiramate-inducedangle-closure glaucoma: cross-sensitivity with other sulphonamide derivatives causing anterior uveitis. Int Ophthalmol. 2014;34(2):345\u20139. https:\/\/doi.org\/10.1007\/s10792-013-9793-8.","journal-title":"Int Ophthalmol"},{"issue":"9","key":"2050_CR8","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.4103\/ijo.IJO_245_19","volume":"67","author":"A Agarwal","year":"2019","unstructured":"Agarwal A. Ciliochoroidal effusion in topiramate-induced bilateral acute angle closure glaucoma. Indian J Ophthalmol. 2019;67(9):1466\u20137. https:\/\/doi.org\/10.4103\/ijo.IJO_245_19.","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"2050_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"key":"2050_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0002-9394(14)73654-2","volume":"15","author":"JT Fan","year":"1993","unstructured":"Fan JT, Johnson DH, Burk RR. Transient myopia,angle closure glaucoma, and choroidal detachment after oral acetazolamide. Am J Ophthalmol. 1993;15:813\u20134.","journal-title":"Am J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-02050-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-021-02050-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-02050-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T03:42:43Z","timestamp":1725507763000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-021-02050-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2050"],"URL":"https:\/\/doi.org\/10.1186\/s12886-021-02050-x","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,27]]},"assertion":[{"value":"12 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This submission complies with the guidelines for human studies and animal welfare regulations. The study adhered to the guidelines by Helsinki declaration This paper does not involve any experimental drug(s) that does not have FDA approval. The treatment of the subjects described in this paper was carried out after obtaining informed consent. No animal experiments were carried out with regards to this submission.The study was approved by the Institutional Review Board of L V Prasad Eye Institute, Hyderabad (LEC-BHR-R-12-20-562) and a written informed consent was taken from the patients for inclusion and for publication in this case series.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A written consent was taken from the patients for inclusion and for publication in this case series.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"287"}}